Critical Inflection Point in FSGS on the Horizon with Nephrologists Poised to Rapidly Adopt New Therapies, According to Spherix Global Insights
EXTON, PA, Aug. 21, 2025 ( GLOBE NEWSWIRE ) -- The treatment landscape for focal segmental glomerulosclerosis ( FSGS ) , a rare and often progressive kidney disease, is approaching a critical inflection point.
MIRM Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View
Mirum surges after second-quarter earnings and revenues top estimates, driven by Livmarli growth and a raised 2025 outlook.
Ligand ( LGND ) Q2 Revenue Jumps 15%
Ligand Pharmaceuticals ( NASDAQ:LGND ) , a biopharma company known for earning royalties from a broad portfolio of drugs, announced results for the second quarter of 2025 on August 7, 2025. The company exceeded analyst estimates with non-GAAP EPS of $1.60 ( consensus: $1.42 ) and reported revenue ...
Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance
Second quarter performance driven by strong portfolio royalty revenue growth of 57% 2025 full year revenue guidance increased to $200 million - $225 million ( previously $180 million - $200 million ) and adjusted earnings per diluted share1 increased to $6.70 - $7.00 ( previously $6.00 - $6.25 )
Travere Therapeutics ( TVTX ) Reports Q2 Loss, Tops Revenue Estimates
Travere (TVTX) delivered earnings and revenue surprises of +50.00% and +17.44%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
PTC Therapeutics ( PTCT ) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mirum Gains 35% in 3 Months: How Should You Play the Stock?
MIRM jumps 35% in 3 months, driven by soaring Livmarli sales and rising demand for its bile acid products.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX - Travere Therapeutics ( NASDAQ:TVTX )
NEW YORK, June 23, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ( "Travere" or the "Company" ) TVTX. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
New Spherix Global Insights Data Reveals 85% of FSGS Patients Have Actively Progressing Disease Despite Treatment, Underscoring Urgent Demand for Innovative Treatments
EXTON, PA, June 10, 2025 ( GLOBE NEWSWIRE ) -- Patients battling focal segmental glomerulosclerosis ( FSGS ) often face a discouraging path, marked by continued disease progression and limited therapeutic options.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX - Travere Therapeutics ( NASDAQ:TVTX )
NEW YORK, June 06, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ( "Travere" or the "Company" ) TVTX. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX - Travere Therapeutics ( NASDAQ:TVTX )
NEW YORK, June 02, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ( "Travere" or the "Company" ) TVTX. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Globant, Doximity, Applied Materials And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Applied Mat ( NASDAQ:AMAT ) , Arrive AI ( NASDAQ:ARAI )
U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Friday. Shares of Globant S.A. GLOB fell sharply in today's pre-market trading after the company reported worse-than-expected first-quarter financial results, issued second-quarter guidance below ...
Mirum's Q1 Earnings Beat Estimates, 2025 Revenue View Raised
MIRM reports better-than-expected first-quarter 2025 results. The company raises its 2025 revenue guidance. Shares rise.
Travere Therapeutics ( TVTX ) Reports Q1 Loss, Tops Revenue Estimates
Travere (TVTX) delivered earnings and revenue surprises of 14.55% and 3%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Vertex Pharmaceuticals ( VRTX ) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Novavax ( NVAX ) Soars 11.4%: Is Further Upside Left in the Stock?
Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Ulta Beauty To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Tuesday - First Watch Restaurant Gr ( NASDAQ:FWRG ) , Delta Air Lines ( NYSE:DAL )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Goldman Sachs cut Genuine Parts Company GPC price target from $133 to $114.
Mirum's Heavy Dependence on Livmarli for Revenues Remains a Woe
MIRM's high reliance on lead drug, Livmarli for revenues remains a worry. Failure to generate sufficient revenues from Livmarli sales is likely to hurt the stock.
Alkaptonuria Therapeutics Market to Reach US$ 31.6 Million by 2035 with Rising Demand for Orphan Drugs - Exclusive Report by Transparency Market Research, Inc.
Wilmington, Delaware, Transparency Market Research, Inc. -, March 18, 2025 ( GLOBE NEWSWIRE ) -- Advancements in rare disease treatments and increasing awareness are driving market growth. The Global Alkaptonuria Therapeutics Market Size was valued at US$ 14.7 Million in 2024 and is projected to ...
Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® ( sparsentan ) for the Treatment of FSGS
Travere announces sNDA submission to FDA based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGS, a rare kidney condition.
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN DIEGO, March 12, 2025 ( GLOBE NEWSWIRE ) -- Travere Therapeutics, Inc. ( NASDAQ: TVTX ) today announced that on March 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 77,200 shares of its common stock to five new ...
MIRM's Q4 Loss Wider Than Expected, Revenues Beat Estimates
Mirum's fourth-quarter 2024 earnings miss estimates while revenues beat the same.
Travere Therapeutics to Participate at Upcoming Investor Conferences - Travere Therapeutics ( NASDAQ:TVTX )
SAN DIEGO, Feb. 24, 2025 ( GLOBE NEWSWIRE ) -- Travere Therapeutics, Inc. TVTX today announced that company management will participate in the following upcoming investor conferences in March: TD Cowen 45th Annual Health Care Conference Presenting on Monday, March 3, 2025, at 9:10 a.m. ET
Travere Therapeutics to Participate at Upcoming Investor Conferences
SAN DIEGO, Feb. 24, 2025 ( GLOBE NEWSWIRE ) -- Travere Therapeutics, Inc. ( NASDAQ: TVTX ) today announced that company management will participate in the following upcoming investor conferences in March: ...
Travere Therapeutics ( TVTX ) Reports Q4 Loss, Tops Revenue Estimates
Travere (TVTX) delivered earnings and revenue surprises of -25.86% and 1.84%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Curious about Travere ( TVTX ) Q4 Performance? Explore Wall Street Estimates for Key Metrics
Get a deeper insight into the potential performance of Travere (TVTX) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
SAN DIEGO, Feb. 13, 2025 ( GLOBE NEWSWIRE ) -- Travere Therapeutics, Inc. ( NASDAQ: TVTX ) today announced it will report fourth quarter and full year 2024 financial results on Thursday, February 20, 2025, after the close of the U.S. financial markets.
Travere Therapeutics ( TVTX ) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Travere (TVTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN DIEGO, Feb. 12, 2025 ( GLOBE NEWSWIRE ) -- Travere Therapeutics, Inc. ( NASDAQ: TVTX ) today announced that on February 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 115,100 shares of its common stock to ten new ...
Travere ( TVTX ) Moves 12.6% Higher: Will This Strength Last?
Travere (TVTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Lattice Semiconductor, SelectQuote, Radiant Logistics And Other Big Stocks Moving Higher On Tuesday - Anterix ( NASDAQ:ATEX ) , Ecolab ( NYSE:ECL )
U.S. stocks were slightly lower, with the Nasdaq Composite falling around 0.1% on Tuesday. Shares of Lattice Semiconductor Corporation LSCC rose sharply during Tuesday's session following quarterly results. Lattice reported quarterly earnings of 15 cents per share, which missed the analyst ...
Travere Therapeutics to Submit sNDA for FILSPARI® ( sparsentan ) in FSGS - Travere Therapeutics ( NASDAQ:TVTX )
Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25 If approved, FILSPARI could be the first and only approved medicine indicated for FSGS, a rare kidney disorder and leading cause of kidney failure
Travere Therapeutics to Submit sNDA for FILSPARI® ( sparsentan ) in FSGS
Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA. submission expected around end of ...
MIRM Shares Rise 12% in a Week on Robust Preliminary 2024 Results
Mirum stock rallies this week on upbeat preliminary 2024 results, the 2025 outlook and anticipated pipeline goals.
Pacira ( PCRX ) Soars 11.1%: Is Further Upside Left in the Stock?
Pacira (PCRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Wall Street Analysts Believe Travere ( TVTX ) Could Rally 42.56%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 42.6% in Travere (TVTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Travere Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 06, 2025 ( GLOBE NEWSWIRE ) -- Travere Therapeutics, Inc., ( NASDAQ: TVTX ) today announced that Eric Dube, Ph.D., president and chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 8:15 a.m. PT.
Travere Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Travere Therapeutics ( NASDAQ:TVTX )
SAN DIEGO, Jan. 06, 2025 ( GLOBE NEWSWIRE ) -- Travere Therapeutics, Inc., TVTX today announced that Eric Dube, Ph.D., president and chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 8:15 a.m. PT.
Mirum Shares Surge More Than 90% in 6 Months: Here's Why
MIRM's lead drug, Livmarli, is driving revenues and the momentum is likely to continue. The company's efforts to build its pipeline beyond Livmarli also hold promise.
Travere Therapeutics to Present at Upcoming Investor Conferences - Travere Therapeutics ( NASDAQ:TVTX )
SAN DIEGO, Nov. 25, 2024 ( GLOBE NEWSWIRE ) -- Travere Therapeutics, Inc., TVTX today announced that company management will present in the following upcoming investor conferences in December: 7th Annual Evercore HealthCONx Conference Tuesday, December 3, 2024, at 10:00 a.m. ET
Travere Therapeutics to Present at Upcoming Investor Conferences
SAN DIEGO, Nov. 25, 2024 ( GLOBE NEWSWIRE ) -- Travere Therapeutics, Inc., ( NASDAQ: TVTX ) today announced that company management will present in the following upcoming investor conferences in December: ...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN DIEGO, Nov. 13, 2024 ( GLOBE NEWSWIRE ) -- Travere Therapeutics, Inc., ( NASDAQ: TVTX ) today announced that on November 10, 2024, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting of inducement restricted stock units, or ...
Mirum's Q3 Earnings Beat Estimates, 2024 Revenue View Raised
MIRM's third-quarter 2024 earnings and revenues surpass estimates. The company increases revenue guidance for 2024. Stock rises in pre-market.
Travere Therapeutics Announces Pricing of Public Offering of Common Stock - Travere Therapeutics ( NASDAQ:TVTX )
SAN DIEGO, Nov. 07, 2024 ( GLOBE NEWSWIRE ) -- Travere Therapeutics, Inc. TVTX today announced the pricing of an underwritten public offering of 7,812,500 shares of its common stock at a price to the public of $16.00 per share. All of the shares are being sold by Travere.
Travere Therapeutics Announces Pricing of Public Offering of Common Stock
SAN DIEGO, Nov. 07, 2024 ( GLOBE NEWSWIRE ) -- Travere Therapeutics, Inc. ( Nasdaq: TVTX ) today announced the pricing of an underwritten public offering of 7,812,500 shares of its common stock at a price to the public of $16.00 per share. All of the shares are being sold by Travere.
Travere Therapeutics to Present at Upcoming Investor Conferences
SAN DIEGO, Nov. 04, 2024 ( GLOBE NEWSWIRE ) -- Travere Therapeutics, Inc., ( NASDAQ: TVTX ) today announced that company management will present in the following upcoming investor conferences in November: ...
Travere Therapeutics ( TVTX ) Reports Q3 Loss, Tops Revenue Estimates
Travere (TVTX) delivered earnings and revenue surprises of 0% and 4.10%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® ( Sparsentan ) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024 - Travere Therapeutics ( NASDAQ:TVTX )
Nearly 60% of patients with IgAN in the SPARTAN Study achieved complete remission when using FILSPARI as first-line treatment SPARTACUS Study, PROTECT open-label extension, and real-world evidence presentations highlight initial safety and efficacy data of FILSPARI in combination treatment in IgAN
Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® ( Sparsentan ) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024
Travere presents data on FILSPARI (sparsentan) in IgAN and FSGS at ASN Kidney Week 2024.
Wall Street Analysts See a 26.27% Upside in Travere ( TVTX ) : Can the Stock Really Move This High?
The mean of analysts' price targets for Travere (TVTX) points to a 26.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
